PCSK9 and diabetes mellitus: Pharmacotherapy with statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and bempedoic acid has convincingly been shown to reduce the cardiovascular risk of people with diabetes.